Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis Journal Article


Authors: Ortiz, M. V.; Fernandez-Ledon, S.; Ramaswamy, K.; Forlenza, C. J.; Shukla, N. N.; Kobos, R.; Heaton, T. E.; LaQuaglia, M. P.; Steinherz, P. G.
Article Title: Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis
Abstract: From 2009 to 2018, 10 consecutive patients with Wilms tumors and bilateral nephroblastomatosis, who had completed standard therapy, were provided a maintenance chemotherapy regimen consisting of vincristine and dactinomycin every 3 months for 12 months in order to prevent an early metachronous Wilms tumor. One patient (10%) with Beckwith-Wiedemann syndrome developed a new tumor, without anaplasia. There were no significant toxicities reported during maintenance. All patients are currently alive with no evidence of disease. Further investigations are recommended to determine the utility of this approach. © 2018 Wiley Periodicals, Inc.
Keywords: chemotherapy; wilms tumor; nephroblastomatosis
Journal Title: Pediatric Blood and Cancer
Volume: 66
Issue: 1
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Date Published: 2019-01-01
Start Page: e27500
Language: English
DOI: 10.1002/pbc.27500
PUBMED: 30334607
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score